HomeCompareKHOLY vs ABBV

KHOLY vs ABBV: Dividend Comparison 2026

KHOLY yields 7.26% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KHOLY wins by $55726.60M in total portfolio value
10 years
KHOLY
KHOLY
● Live price
7.26%
Share price
$20.55
Annual div
$1.49
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55726.70M
Annual income
$54,289,294,443.38
Full KHOLY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KHOLY vs ABBV

📍 KHOLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKHOLYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KHOLY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KHOLY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KHOLY
Annual income on $10K today (after 15% tax)
$616.72/yr
After 10yr DRIP, annual income (after tax)
$46,145,900,276.87/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KHOLY beats the other by $46,145,879,220.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KHOLY + ABBV for your $10,000?

KHOLY: 50%ABBV: 50%
100% ABBV50/50100% KHOLY
Portfolio after 10yr
$27863.40M
Annual income
$27,144,659,607.57/yr
Blended yield
97.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KHOLY
No analyst data
Altman Z
0.7
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KHOLY buys
0
ABBV buys
0
No recent congressional trades found for KHOLY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKHOLYABBV
Forward yield7.26%3.06%
Annual dividend / share$1.49$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$55726.70M$102.3K
Annual income after 10y$54,289,294,443.38$24,771.77
Total dividends collected$55628.12M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KHOLY vs ABBV ($10,000, DRIP)

YearKHOLY PortfolioKHOLY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,151$1,451.11$11,550$430.00+$601.00KHOLY
2$16,298$3,295.82$13,472$627.96+$2.8KKHOLY
3$25,701$8,262.58$15,906$926.08+$9.8KKHOLY
4$51,855$24,355.05$19,071$1,382.55+$32.8KKHOLY
5$147,335$91,849.62$23,302$2,095.81+$124.0KKHOLY
6$645,443$487,794.83$29,150$3,237.93+$616.3KKHOLY
7$4,684,887$3,994,263.14$37,536$5,121.41+$4.65MKHOLY
8$59,203,468$54,190,639.22$50,079$8,338.38+$59.15MKHOLY
9$1,343,372,944$1,280,025,233.25$69,753$14,065.80+$1343.30MKHOLY
10$55,726,703,494$54,289,294,443.38$102,337$24,771.77+$55726.60MKHOLY

KHOLY vs ABBV: Complete Analysis 2026

KHOLYStock

Koç Holding A.S., through its subsidiaries, engages in the energy, automotive, consumer durables, finance, and other businesses in Turkey and internationally. The company's energy business operates petroleum refineries; distributes petroleum products and liquefied petroleum gases; and generates electricity through hydroelectric, natural gas, coal, thermal, and solar power and other renewable plants. It serves customers under the Akpa, Aygaz, Lipetgaz, Mogaz, Pursu, Aygaz Dogalaz, Demir Export, Ditas, Opet Fuchs, Opet, THY Opet, Tupras, Elektra Bregenz, and Entek brand names. The company's automotive business provides light commercial vehicles, passenger cars, tractors, buses, and trucks, as well as offers automotive retailing and car rental services. It serves customers under the Ford, Koç Fiat Kredi, Otokar, Avis, Birmot, Budget, Otokoç, Otokoç Otomotiv, Otokoç Sigorta, Alfa Romeo, Ferrari, Fiat, Lancia, Maserati, Otoeksper, Tofas, Case IH, and TürkTraktör. The company's consumer durables business offers white goods, televisions, and air conditioners under the Arçelik, Beko, Leisure, Arctic, Altus, Grundig, Blomberg, Defy, Elektra Bregenz, Flavel, Arçelik LG, TEE, and WAT brand names. Its finance business provides various banking and financial products and services that include private banking, factoring, leasing, portfolio management, and credit cards under the Koçfinans, Yapi Kredi Bankasi, Token, akpakoc, Yapi Kredi Faktoring, Yapi Kredi, Yapi Kredi Leasing, Yapi Kredi Kültür Sanat Yayincilik, Yapi Kredi Portföy Yönetimi, Yapi Kredi Yatirim, and Yapi Kredi Koray brand names. The company's other business offers tomato products and pastes, canned pickles, and ketchups; and pasteurized milk, as well as do it yourself retailing, marina, tourism, and information technology services under various brand names. The company was founded in 1926 and is based in Istanbul, Turkey.

Full KHOLY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KHOLY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KHOLY vs SCHDKHOLY vs JEPIKHOLY vs OKHOLY vs KOKHOLY vs MAINKHOLY vs JNJKHOLY vs MRKKHOLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.